Has Dayna Miyashiro received payments from drug or device companies?

Yes. Drug and device makers reported $6,087 in general payments to Dayna Miyashiro across 132 transactions between 2019–2025. Most Open Payments records nationally are meals worth under $20; a reported payment is not evidence of wrongdoing.

Does a payment mean Dayna Miyashiro did something wrong?

No. Federal law requires drug and device makers to report almost every transfer of value to a physician, including a $14 sandwich at a lunch presentation. Consulting fees, research funding and royalties to device inventors are ordinary, legal parts of medicine. This site reports what was disclosed; it makes no allegation.

Where does this information about Dayna Miyashiro come from?

The U.S. Centers for Medicare & Medicaid Services. Payments come from Open Payments, published under the Physician Payments Sunshine Act. Billing and prescribing figures come from the Medicare Physician & Other Practitioners and Part D Prescriber public use files for 2024.

Dayna Miyashiro

Allergy & Immunology · Vista, CANPI 1699158493

Payments from drug & device makers

What this record shows

This record is dominated by food and beverage: $5,287 of the $6,087 with a category attached, or 86.9%. It is spread thinly across 27 manufacturers, the largest accounting for just 20.9% — the pattern of someone who eats at a lot of different presentations.

$6,087in general payments, 2019–2025

Across 132 payments — averaging $46.11 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

Sanofi$1K
GSK$1K
AstraZeneca$825
Grifols USA, LLC$583
Takeda Pharmaceuticals U.S.A., Inc.$400
Regeneron Healthcare Solutions, Inc.$287
plus $2K from 21 others

What the payments were for

Grants$80013%
Food & beverage$5,28787%

Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.

General payments by program year

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

Company	Payments	Total
Sanofi	14	$1,275
GSK	27	$1,113
AstraZeneca	13	$825
Grifols USA, LLC	14	$583
Takeda Pharmaceuticals U.S.A., Inc.	12	$400
Regeneron Healthcare Solutions, Inc.	3	$287
Blueprint Medicines Corporation	6	$249
Genentech USA, Inc.	3	$232
Amgen(2 entities)	3	$160
Novartis	6	$136
Galderma Laboratories, L.p.	1	$132
CSL Behring	6	$128
Alk-abello, Inc	3	$74
Ionis Pharmaceuticals, Inc.	2	$68
ARS Pharmaceuticals Operations, Inc.	2	$55
Boehringer Ingelheim	3	$51
Incyte Corporation	2	$42
Phadia US Inc.	2	$41
Biocryst US Sales Co., LLC	1	$36
Abbott	2	$35
Genentech, Inc.	1	$35
Pharming Healthcare, Inc.	1	$28
Tersera Therapeutics LLC	1	$28
Biogen	1	$26
Lilly USA, LLC	1	$21
Azurity Pharmaceuticals, Inc.	1	$15
Johnson & Johnson	1	$15

What the payments were tied to

Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.

How this compares

$6,087 in reported general payments places this provider in the 65th percentile of 426 allergy & immunology providers in California.

See all allergy & immunology providers in California →

Other allergy & immunology in Vista

Raffi TachdjianSanta Monica$3.7M
Bob GengSan Diego$3.3M
Vinay MehtaLaguna Niguel$1.3M
Andrew WhiteSan Diego$752K
Marc RiedlSan Diego$725K
Katharine WoessnerSan Diego$581K
Brian Modenala Jolla$453K
Heena Shah PatelUpland$428K
Jacob OffenbergerGranada Hills$419K
Myron LiebhaberSanta Barbara$354K

See the full list for California →

Where these figures come from

Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
Identity: NPPES NPI Registry, July 2026.

Is this you, or does something look wrong? →